Metabolomic Signatures Linking Physical Frailty to Liver Disease in UK Biobank

244,187 UK Biobank participants were analyzed over a median follow-up of 13.7 years to identify metabolic links between physical frailty and liver disease. A 96-metabolite signature was constructed and found to mediate 4.25% of the association between frailty and incident metabolic dysfunction-associated steatotic liver disease (MASLD). The data, authored by Doudou Li and shared under a CC-BY-4.0 license, was last updated in May 2026.

Use Cases

• Train predictive models for MASLD risk based on a frailty-associated metabolic signature.
• Conduct mediation analysis to understand metabolic pathways linking physical frailty to hepatic steatosis.
• Validate findings on the association between pre-frail/frail status and incident MASLD risk.
• Perform feature selection and biomarker discovery from the 96-metabolite signature.

Strengths

• Large cohort of 244,187 participants from the UK Biobank.
• Longitudinal design with a median follow-up of 13.7 years.
• Identifies a specific 96-metabolite signature with quantified mediating effect (4.25%).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the UK Biobank source.

Provenance

Source

UK Biobank

Collection Method

Prospective cohort study analyzing hospital records, death registries, and metabolomic data.

Time Range

Median follow-up of 13.7 years.

Freshness

Last updated 2026-05-12 04:19:02; freshness should be verified.

Geography

United Kingdom